We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aspen Pharmacare (APNHY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aspen Pharmacare is a member of our Medical group, which includes 916 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that APNHY has returned about 42.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.9% on average. This shows that Aspen Pharmacare is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Corcept Therapeutics (CORT - Free Report) . The stock has returned 234% year-to-date.
Over the past three months, Corcept Therapeutics' consensus EPS estimate for the current year has increased 249.3%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, which includes 12 individual stocks and currently sits at #43 in the Zacks Industry Rank. This group has gained an average of 7.9% so far this year, so APNHY is performing better in this area.
On the other hand, Corcept Therapeutics belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #157. The industry has moved -7.5% year to date.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Corcept Therapeutics. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aspen Pharmacare (APNHY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Aspen Pharmacare is a member of our Medical group, which includes 916 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aspen Pharmacare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for APNHY's full-year earnings has moved 7.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that APNHY has returned about 42.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.9% on average. This shows that Aspen Pharmacare is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Corcept Therapeutics (CORT - Free Report) . The stock has returned 234% year-to-date.
Over the past three months, Corcept Therapeutics' consensus EPS estimate for the current year has increased 249.3%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aspen Pharmacare belongs to the Medical - Generic Drugs industry, which includes 12 individual stocks and currently sits at #43 in the Zacks Industry Rank. This group has gained an average of 7.9% so far this year, so APNHY is performing better in this area.
On the other hand, Corcept Therapeutics belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #157. The industry has moved -7.5% year to date.
Investors with an interest in Medical stocks should continue to track Aspen Pharmacare and Corcept Therapeutics. These stocks will be looking to continue their solid performance.